Thermo Fisher Scientific is one of the largest global suppliers of scientific instruments, reagents, and laboratory services. In recent Thermo Fisher news, the company will acquire Clario Holdings, Inc.
This article reviews the Clario acquisition, recent advancements in Thermo Fisher’s technology and services portfolio, and its latest financial results.
Thermo Fisher to Acquire Clario in $9.4 Billion Deal
Thermo Fisher announced on Wednesday, October 29, that it will be purchasing Clario for $9.4 billion.
Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials, in a cash transaction valued at $8.875 billion. ➡️ https://t.co/Dv6xAEiqgG#pharmanews #acquisition #clinicaltrials pic.twitter.com/6CM6d4k1qS
— Contract Pharma (@ContractPharma) October 29, 2025
Clario is a private company that creates digital tools for clinical trial data.
The agreement has an initial payment of about $8.88 billion, plus $125 million that will be paid in early 2027.
There’s $400 million more that depends on how well Clario performs over the coming two years.
The deal is Thermo Fisher’s third acquisition this year, and its largest to date.
Thermo Fisher anticipates Clario to generate about $1.25 billion in revenue by 2025.
The sale is also scheduled to be completed in early 2026.
Thermo Fisher said that after the deal was completed, it would probably raise its adjusted earnings per share by 45 cents in the first year.
Thermo Fisher Introduces Groundbreaking Orbitrap Mass Detector Technology
On October 23, Thermo Fisher introduced the Orbitrap Exploris EFOX Mass Detector – the world’s first high-resolution accurate mass instrument for environmental and food safety labs.
This technology will aid labs in meeting new, tighter global testing requirements for contaminants such as PFAS, pesticides, and other toxic compounds in water and food sources.
The Orbitrap Exploris EFOX also directly links to the Chromeleon Chromatography Data System.
This configuration allows a user-friendly setup, leading the operator through the various phases of analysis and delivering faster, traceable results.
Labs employing the system can provide better quality data without having to increase cycle time.
Thermo Fisher Reports Strong Q3 2025 Financial Results
In other Thermo Fisher news, the company released its third-quarter results on October 22, reporting solid growth across its business.
Thermo Fisher reported $11.12 billion in revenue for the quarter that ended September 27, 2025, an increase of 5%.
GAAP diluted earnings per share held steady at $4.27. Adjusted earnings per share was $5.79, for a gain of 10% from the prior year.
The company said the gains reflected continued demand in bioproduction, diagnostics and applied markets.
Thermo Fisher News: Conclusion
Thermo Fisher continues to show disciplined growth across its business.
The company has positioned itself to support expanded clinical research, regulatory testing, and pharmaceutical production without compromising on efficiency.
From a financial standpoint, consistency matters more now than volume. Investors should look for stable operating margins, disciplined cash deployment, and early signs that newer segments are contributing meaningfully to earnings.
To stay informed on Thermo Fisher and other corporate finance updates on healthcare, biotech, and data-driven industries, subscribe to the Financial Daily Update today.
Latest News
-
Novartis News: Avidity Acquisition, Immunology Breakthroughs, & Key Updates
-
T. Rowe Price: First Crypto ETF, Leadership Appointments, & More
-
Veeam: Securiti AI Deal, Innovations, and More
-
Kroger News: 2025 Holiday Hiring & Q2 Earnings Update
-
Archer Aviation News: Lilium Patent Deal, Midnight Flight Record, & Earnings
-
JPMorgan News: National Security Push, Bournemouth Project, & Coinbase Deal
-
Johnson & Johnson News: Orthopedics Spinoff, Acquisition Plans, Talc Cancer Case & More
